Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project

Toxicology in Vitro

Volumn 24, Issue 7, 2010, Pages 1879-1889

  Gómez Lechón, María José ^a,b   Tolosa, Laia ^a   Castell, José V ^a,b,c   Donato, María Teresa ^a,b,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

FP6 project; Hepatotoxicity; Hepatotoxicity assay; LIINTOP; Mechanisms of toxicity; Model hepatotoxin; REACH; Selection criteria

Indexed keywords

ACETYLSALICYLIC ACID; AFLATOXIN B; AMODIAQUINE; AMPHETAMINE; AZATHIOPRINE; BUPRENORPHINE; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; DICLOFENAC; ETHINYLESTRADIOL; FIALURIDINE; FLUTAMIDE; ISONIAZID; MENADIONE; MEVINOLIN; N ACETYL 1,4 BENZOQUINONE IMINE; ORPHENADRINE; PARACETAMOL; PARAQUAT; PENTACHLOROPHENOL; PERHEXILINE; PHENYTOIN; ROTENONE; STAVUDINE; TACRINE; THIOACETAMIDE; TIENILIC ACID; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID;

APOPTOSIS; CHOLESTASIS; CLINICAL PROTOCOL; DRUG EXPOSURE; EXPERIMENTAL MODEL; FATTY LIVER; HUMAN; IN VITRO STUDY; INTESTINE ABSORPTION; LIPIDOSIS; LIVER METABOLISM; LIVER TOXICITY; MITOCHONDRION; OXIDATIVE STRESS; REVIEW; TOXICITY TESTING;

ANIMALS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS;

EID: 77957021236     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.07.018     Document Type: Review

References (72)

1. Abboud G., Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007, 30:277-294.
2. Amacher D.E. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol. Appl. Pharmacol. 2010, 245:134-142.
3. Beger R.D., Sun J., Schnackenberg L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 2010, 243:154-166.
4. Blomme E.A., Yang Y., Waring J.F. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 2009, 186:22-31.
5. Bondesson I., Ekwall B., Hellberg S., Romert L., Stenberg K., Walum E. MEIC - a new international multicenter project to evaluate the relevance to human toxicity of in vitro cytotoxicity tests. Cell Biol. Toxicol. 1989, 5:331-347.
6. Bradbury M.W., Berk P.D. Lipid metabolism in hepatic steatosis. Clin. Liver Dis. 2004, 8:639-671. (xi).
7. Chariot P., Drogou I., de Lacroix-Szmania I., Eliezer-Vanerot M.C., Chazaud B., Lombes A., Schaeffer A., Zafrani E.S. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J. Hepatol. 1999, 30:156-160.
8. Chatman L.A., Morton D., Johnson T.O., Anway S.D. A strategy for risk management of drug-induced phospholipidosis. Toxicol. Pathol. 2009, 37:997-1005.
9. Criddle D.N., Gillies S., Baumgartner-Wilson H.K., Jaffar M., Chinje E.C., Passmore S., Chvanov M., Barrow S., Gerasimenko O.V., Tepikin A.V., Sutton R., Petersen O.H. Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J. Biol. Chem. 2006, 281:40485-40492.
10. Cullen J.M. Mechanistic classification of liver injury. Toxicol. Pathol. 2005, 33:6-8.
11. Dambach D.M., Andrews B.A., Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 2005, 33:17-26.
12. Donato M.T., Martinez-Romero A., Jimenez N., Negro A., Herrera G., Castell J.V., O'Connor J.E., Gomez-Lechon M.J. Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem. Biol. Interact. 2009, 181:417-423.
13. Feldmann G. Liver apoptosis. Gastroenterol. Clin. Biol. 2006, 30:533-545.
14. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 1995, 67:101-154.
15. Fromenty B., Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J. Hepatol. 1997, 26(Suppl. 2):43-53.
16. Geier A., Dietrich C.G., Gerloff T., Haendly J., Kullak-Ublick G.A., Stieger B., Meier P.J., Matern S., Gartung C. Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. Biochim. Biophys. Acta 2003, 1609:87-94.
17. Gomez-Lechon M.J., O'Connor E., Castell J.V., Jover R. Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes. Toxicol. Sci. 2002, 65:299-308.
18. Gomez-Lechon M.J., Ponsoda X., O'Connor E., Donato T., Jover R., Castell J.V. Diclofenac induces apoptosis in hepatocytes. Toxicol. in Vitro 2003, 17:675-680.
19. Gomez-Lechon M.J., O'Connor J.E., Lahoz A., Castell J.V., Donato M.T. Identification of apoptotic drugs: multiparametric evaluation in cultured hepatocytes. Curr. Med. Chem. 2008, 15:2071-2085.
20. Gomez-Lechon M.J., Lahoz A., Gombau L., Castell J.V., Donato M.T. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr. Pharm. Des. 2010, 16:1963-1977.
21. Greim H., Arand M., Autrup H., Bolt H.M., Bridges J., Dybing E., Glomot R., Foa V., Schulte-Hermann R. Toxicological comments to the discussion about REACH. Arch. Toxicol. 2006, 80:121-124.
22. Halle W. The Registry of Cytotoxicity: toxicity testing in cell cultures to predict acute toxicity (LD50) and to reduce testing in animals. Altern. Lab. Anim. 2003, 31:89-198.
23. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 1997, 25:53-60.
24. Hanley P.J., Ray J., Brandt U., Daut J. Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J. Physiol. 2002, 544:687-693.
25. Hartung T., Bremer S., Casati S., Coecke S., Corvi R., Fortaner S., Gribaldo L., Halder M., Hoffmann S., Roi A.J., Prieto P., Sabbioni E., Scott L., Worth A., Zuang V. A modular approach to the ECVAM principles on test validity. Altern. Lab. Anim. 2004, 32:467-472.
26. Hofer T., Gerner I., Gundert-Remy U., Liebsch M., Schulte A., Spielmann H., Vogel R., Wettig K. Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Arch. Toxicol. 2004, 78:549-564.
27. Hynes J., Marroquin L.D., Ogurtsov V.I., Christiansen K.N., Stevens G.J., Papkovsky D.B., Will Y. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol. Sci. 2006, 92:186-200.
28. IEH (Institute of Environment and Health), 2001. Assessment of the Feasibility of Replacing Current Regulatory In Vivo Toxicity Tests with In Vitro Tests within the Framework Specified in the EC White Paper " Strategy for an EU Chemicals Policy" (Web Report 10). IEH, Leicester, UK, December 2001. Available through <> (consulted October 2007). http://www.silsoe.cranfield.ac.uk/ieh/pdf/w10.pdf.
29. Ioannides C., Lewis D.F. Cytochromes P450 in the bioactivation of chemicals. Curr. Top. Med. Chem. 2004, 4:1767-1788.
30. Johannsen D.L., Ravussin E. The role of mitochondria in health and disease. Curr. Opin. Pharmacol. 2009, 9:780-786.
31. Jones D.P., Lemasters J.J., Han D., Boelsterli U.A., Kaplowitz N. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol. Interv. 2010, 10:98-111.
32. Kang P., Dalvie D., Smith E., Zhou S., Deese A., Nieman J.A. Bioactivation of flutamide metabolites by human liver microsomes. Drug Metab. Dispos. 2008, 36:1425-1437.
33. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci. 2006, 90:133-141.
34. Kass G.E. Mitochondrial involvement in drug-induced hepatic injury. Chem. Biol. Interact. 2006, 163:145-159.
35. Kass G.E., Macanas-Pirard P., Lee P.C., Hinton R.H. The role of apoptosis in acetaminophen-induced injury. Ann. NY Acad. Sci. 2003, 1010:557-559.
36. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 2008, 22:335-353.
37. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003, 349:474-485.
38. Letteron P., Sutton A., Mansouri A., Fromenty B., Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003, 38:133-140.
39. Li A.P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the " multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 2002, 142:7-23.
40. Loranger A., Barriault C., Yousef I.M., Tuchweber B. Structural and functional alterations of hepatocytes during transient phalloidin-induced cholestasis in the rat. Toxicol. Appl. Pharmacol. 1996, 137:100-111.
41. Marion T.L., Leslie E.M., Brouwer K.L. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol. Pharm. 2007, 4:911-918.
42. Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab. Pharmacokinet. 2006, 21:347-356.
43. Moridani M.Y., Cheon S.S., Khan S., O'Brien P.J. Metabolic activation of 3-hydroxyanisole by isolated rat hepatocytes. Chem. Biol. Interact. 2003, 142:317-333.
44. Nioi P., Perry B.K., Wang E.J., Gu Y.Z., Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol. Sci. 2007, 99:162-173.
45. Nonoyama T., Fukuda R. Drug-induced phospholipidosis - pathological aspects and its prediction. J. Toxicol. Pathol. 2008, 21:9-34.
46. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
47. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
48. Palmeira C.M., Rolo A.P. Mitochondrially-mediated toxicity of bile acids. Toxicology 2004, 203:1-15.
49. Pappu A., Hostetler K.Y. Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A. Biochem. Pharmacol. 1984, 33:1639-1644.
50. Park B.K., Kitteringham N.R., Maggs J.L., Pirmohamed M., Williams D.P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 2005, 45:177-202.
51. Park K., Williams D.P., Naisbitt D.J., Kitteringham N.R., Pirmohamed M. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 2005, 207:425-434.
52. Pauli-Magnus C., Meier P.J. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006, 44:778-787.
53. Pereira C.V., Moreira A.C., Pereira S.P., Machado N.G., Carvalho F.S., Sardao V.A., Oliveira P.J. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety?. Curr. Drug Saf. 2009, 4:34-54.
54. Pessayre D., Mansouri A., Berson A., Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb. Exp. Pharmacol. 2010, 311:365.
55. Reasor M.J., Kacew S. Drug-induced phospholipidosis: are there functional consequences?. Exp. Biol. Med. (Maywood) 2001, 226:825-830.
56. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 2006, 5:567-583.
57. Reddy M.V., Storer R.D., Laws G.M., Armstrong M.J., Barnum J.E., Gara J.P., McKnight C.G., Skopek T.R., Sina J.F., DeLuca J.G., Galloway S.M. Genotoxicity of naturally occurring indole compounds: correlation between covalent DNA binding and other genotoxicity tests. Environ. Mol. Mutagen. 2002, 40:1-17.
58. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 Concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), Establishing a European Chemicals Agency, Amending Directive 1999/45/EC and Repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Official Journal L396, 30/12/2006, p. 1; Corrected Official Journal L136, 29/05/2007, p. 3.
59. Rolo A.P., Oliveira P.J., Seica R., Santos M.S., Moreno A.J., Palmeira C.M. Disruption of mitochondrial calcium homeostasis after chronic alpha-naphthylisothiocyanate administration: relevance for cholestasis. J. Invest. Med. 2002, 50:193-200.
60. Roman I.D., Fernandez-Moreno M.D., Fueyo J.A., Roma M.G., Coleman R. Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets. Toxicol. Sci. 2003, 71:276-281.
61. Russmann S., Kullak-Ublick G.A., Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 2009, 16:3041-3053.
62. 2 and cumene hydroperoxide treatment on heart mitochondria. J. Bioenerg. Biomembr. 2006, 38:121-127.
63. Sawada H., Takami K., Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 2005, 83:282-292.
64. Shokolenko I., Venediktova N., Bochkareva A., Wilson G.L., Alexeyev M.F. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009, 37:2539-2548.
65. Sokol R.J., Dahl R., Devereaux M.W., Yerushalmi B., Kobak G.E., Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J. Pediatr. Gastroenterol. Nutr. 2005, 41:235-243.
66. Spielmann H. Collaboration between ZEBET, FRAME, and ECVAM: FRAME's contribution to establishing the three Rs in Europe. Altern. Lab. Anim. 2009, 37(Suppl. 2):23-27.
67. Tang W. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 2007, 3:407-420.
68. Thibault N., Claude J.R., Ballet F. Actin filament alteration as a potential marker for cholestasis: a study in isolated rat hepatocyte couplets. Toxicology 1992, 73:269-279.
69. Vinken M., Doktorova T., Ellinger-Ziegelbauer H., Ahr H.J., Lock E., Carmichael P., Roggen E., van Delft J., Kleinjans J., Castell J., Bort R., Donato T., Ryan M., Corvi R., Keun H., Ebbels T., Athersuch T., Sansone S.A., Rocca-Serra P., Stierum R., Jennings P., Pfaller W., Gmuender H., Vanhaecke T., Rogiers V. The carcinoGENOMICS project: critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays. Mutat. Res. 2008, 659:202-210.
70. Xu J.J., Diaz D., O'Brien P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 2004, 150:115-128.
71. Yuan L., Kaplowitz N. Glutathione in liver diseases and hepatotoxicity. Mol. Aspects Med. 2009, 30:29-41.
72. Zollner G., Trauner M. Mechanisms of cholestasis. Clin. Liver Dis. 2008, 12:1-26. (vii).